Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis

被引:24
|
作者
Tatar, Ovidiu [1 ]
Thompson, Erika [2 ]
Naz, Anila [1 ]
Perez, Samara [1 ,3 ]
Shapiro, Gilla K. [1 ,3 ]
Wade, Kristina [1 ]
Zimet, Gregory [4 ]
Gilca, Vladimir [5 ]
Janda, Monika [6 ]
Kahn, Jessica [7 ]
Daley, Ellen [8 ]
Rosberger, Zeev [1 ,3 ]
机构
[1] Jewish Gen Hosp, Lady Davis Inst Med Res, 4333 Cote Ste Catherine Rd, Montreal, PQ H3T 1E4, Canada
[2] Univ North Texas, Hlth Sci Ctr, Sch Publ Hlth, Dept Hlth Behav & Hlth Syst, 3500 Camp Bowie,EAD 709M, Ft Worth, TX 76107 USA
[3] McGill Univ, Dept Psychol, 2001 McGill Coll, Montreal, PQ, Canada
[4] Indiana Univ Sch Med, Sect Adolescent Med, 410 West 10th St,HS 1001, Indianapolis, IN 46202 USA
[5] Inst Natl Sante Publ Quebec, 945 Wolfe Ave, Quebec City, PQ G1V 5B3, Canada
[6] Queensland Univ Technol, Fac Hlth, Brisbane, Qld, Australia
[7] Univ Cincinnati Ohio, Cincinnati Childrens Hosp Med Ctr, Div Adolescent & Transit Med, MLC 4000,3333 Burnet Ave, Cincinnati, OH 45229 USA
[8] Univ S Florida, Dept Community & Family Hlth, 13201 Bruce B Downs Blvd,MDC 56, Tampa, FL 33612 USA
关键词
Human papillomavirus; Uterine Cervical Neoplasms; Mass Screening; Psychology; Human Papillomavirus DNA Tests; Review; Mixed methods; Barriers; Facilitators; Psychosocial; INTRAEPITHELIAL NEOPLASIA; QUALITY-ASSURANCE; DECISION-MAKING; FOLLOW-UP; KNOWLEDGE; WOMEN; INFORMATION; VACCINATION; PREFERENCES; PREDICTORS;
D O I
10.1016/j.ypmed.2018.08.034
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Primary screening for cervical cancer is transitioning from the longstanding Pap smear towards implementation of an HPV-DNA test, which is more sensitive than Pap cytology in detecting high-risk lesions and offers greater protection against invasive cervical carcinomas. Based on these results, many countries are recommending and implementing HPV testing-based screening programs. Understanding what factors (e.g., knowledge, attitudes) will impact on HPV test acceptability by women is crucial for ensuring adequate public health practices to optimize cervical screening uptake. We used mixed methods research synthesis to provide a categorization of the relevant factors related to HPV primary screening for cervical cancer and describe their influence on women's acceptability of HPV testing. We searched Medline, Embase, PsycINFO, CINAHL, Global Health and Web of Science for journal articles between January 1, 1980 and October 31, 2017 and retained 22 empirical articles. Our results show that while most factors associated with HPV test acceptability are included in the Health Belief Model and/or Theory of Planned Behavior (e.g., attitudes, knowledge), other important factors are not encompassed by these theoretical frameworks (e.g., health behaviors, negative emotional reactions related to HPV testing). The direction of influence of psychosocial factors on HPV test acceptability was synthesized based on 14 quantitative studies as: facilitators (e.g., high perceived HPV test benefits), barriers (e.g., negative attitudes towards increased screening intervals), contradictory evidence (e.g., sexual history) and no impact (e.g., high perceived severity of HPV infection). Further population-based studies are needed to confirm the impact of these factors on HPV-based screening acceptability.
引用
收藏
页码:40 / 50
页数:11
相关论文
共 50 条
  • [41] ARTISTIC: a randomised trial of-human-papillomavirus (HPV) testing in primary cervical screening
    Kitchener, H. C.
    Almonte, M.
    Gilham, C.
    Dowie, R.
    Stoykova, B.
    Sargent, A.
    Roberts, C.
    Desai, M.
    Peto, J.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 (51) : 1 - +
  • [42] Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening
    Boers, Aniek
    Wang, Rong
    Slagter-Menkema, Lorian
    van Hemel, Bettien M.
    Ghyssaert, Hilde
    van der Zee, Ate G. J.
    Wisman, G. Bea A.
    Schuuring, Ed
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (12) : 4391 - 4393
  • [43] Acceptability of deferring the start of cervical cancer screening to age 30 for women vaccinated against human papillomavirus
    Martello, Gessica
    Gori, Silvia
    Frayle, Helena
    Franceschi, Silvia
    Zorzi, Manuel
    Del Mistro, Annarosa
    PREVENTIVE MEDICINE REPORTS, 2023, 36
  • [44] Should human papillomavirus DNA testing be offered in combination with cytology or as a sole primary screening test in cervical cancer prevention?
    Tristram, Amanda
    FUTURE ONCOLOGY, 2012, 8 (07) : 783 - 786
  • [45] Age patterns of human papillomavirus infection as primary screening test for cervical cancer and subsequent triage with visual inspection in Honduras
    Sandoval, Manuel
    Holme, Francesca
    Lobo, Saul
    Slavkovsky, Rose
    Thomson, Kerry A.
    Jeronimo, Jose
    Figueroa, Jacqueline
    de Sanjose, Silvia
    SALUD PUBLICA DE MEXICO, 2020, 62 (05): : 487 - 493
  • [46] Acceptability of self-collected human papillomavirus specimens in cervical cancer screening: A review
    Brenda L Quincy
    World Journal of Obstetrics and Gynecology, 2014, (03) : 90 - 97
  • [47] Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening
    Tota, Joseph E.
    Bentley, James
    Blake, Jennifer
    Coutlee, Francois
    Duggan, Maire A.
    Ferenczy, Alex
    Franco, Eduardo L.
    Fung-Kee-Fung, Michael
    Gotlieb, Walter
    Mayrand, Marie-Helene
    McLachlin, Meg
    Murphy, Joan
    Ogilvie, Gina
    Ratnam, Sam
    PREVENTIVE MEDICINE, 2017, 98 : 15 - 20
  • [48] Acceptability of self-sampling human papillomavirus test for cervical cancer screening in Japan: A questionnaire survey in the ACCESS trial
    Fujita, Misuzu
    Nagashima, Kengo
    Shimazu, Minobu
    Suzuki, Misae
    Tauchi, Ichiro
    Sakuma, Miwa
    Yamamoto, Setsuko
    Hanaoka, Hideki
    Shozu, Makio
    Tsuruoka, Nobuhide
    Kasai, Tokuzo
    Hata, Akira
    PLOS ONE, 2023, 18 (06):
  • [49] Abbott Alinity m HR-HPV, a novel human papillomavirus assay for primary cervical cancer screening, is adapted to HPV guidelines
    Mouna, Lina
    Pallier, Coralie
    Deback, Claire
    Proust, Stephanie
    Hottelet, Corinne
    Prevot, Sophie
    Roque-Afonso, Anne-Marie
    JOURNAL OF CLINICAL VIROLOGY PLUS, 2021, 1 (04):
  • [50] Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
    Burger, E. A.
    Ortendahl, J. D.
    Sy, S.
    Kristiansen, I. S.
    Kim, J. J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (09) : 1571 - 1578